...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.
【24h】

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

机译:评价将基因转移到非肥胖型糖尿病/重症合并免疫缺陷疾病小鼠再造细胞中的不同方案。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model. METHODS: An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only. RESULT: While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 +/- 2.3 vs. 22.1 +/- 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 +/- 0.9 vs. 11.6 +/- 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 +/- 1.7 vs. 36.5 +/-9.4%) and EGFP expression in these cells (0 +/- 0 vs. 11.3 +/- 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFbeta11-EGFP, high transduction rates for CD45+ (41.0 +/- 5.3%) and CD34+ (38.5 +/- 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 +/- 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 +/- 2.0%), myeloid (36.5 +/- 3.5%) and CD34+ cells (10.1 +/- 1.5%). CONCLUSION: Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFbeta11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.
机译:目的:尽管逆转录病毒载体的基因转移在确定的背景下已显示出独特的临床成功,但是对造血祖细胞的有效遗传操作仍然是一个挑战。为了解决这个问题,我们评估了非肥胖型糖尿病(NOD)/严重合并免疫缺陷疾病(SCID)异种移植模型中的不同转导方案和逆转录病毒构建体。方法:将需要144小时体外操作的扩展转导方案与仅需要96小时的更常规方案进行了比较。结果:在对逆转录病毒载体转导的细胞进行移植前分析时,表达增强的绿色荧光蛋白(EGFP)标记基因,表明扩展方案的总转导率显着更高(33.6 +/- 2.3对22.1 +/- 3.8%) ,移植前CD34 +细胞中EGFP的表达(4.0 +/- 0.9对11.6 +/- 2.5%),人类细胞在移植后4周内植入NOD / SCID骨髓中(4.5 +/- 1.7对36.5 +/-) 9.4%)和EGFP在这些细胞中的表达(0 +/- 0对11.3 +/- 2.8%)显着受损。当96小时实验方案与脾脏聚焦形成病毒(SFFV)/鼠胚胎干细胞(MESV)杂交载体SFbeta11-EGFP结合使用时,CD45 +(41.0 +/- 5.3%)和CD34 +(38.5 +检测到移植前细胞的迁移率(3.7%),以及移植后4周在NOD / SCID小鼠中的有效人类细胞移植率(32.4 +/- 3.5%)。在B淋巴瘤(15.9 +/- 2.0%),骨髓(36.5 +/- 3.5%)和CD34 +细胞(10.1 +/- 1.5%)中观察到转基因表达。结论:我们的数据表明,在细胞因子中维持多天的CD34 +细胞可能分化并失去了其对NOD / SCID小鼠血液学重建的贡献。此外,SFFV / MESV杂种载体SFbeta11-EGFP允许在造血祖细胞中有效转导和基因表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号